The U.S. Food and Drug Administration (FDA) approved a self-injected version of Saphnelo (anifrolumab-fnia), known as Saphnelo Pen.

Answering the question "How are you?" can be complicated when living with lupus, but it's OK to not be OK, says columnist ...

Lupkynis (voclosporin) is now approved in Japan to treat lupus nephritis, a complication of lupus marked by kidney damage and inflammation. The Japanese Ministry of Health, Labour, and Welfare ...

Telitacicept, a B-cell-targeting therapy developed by RemeGen, outperformed a placebo at reducing the severity of systemic lupus erythematosus (SLE) in a Phase 3 clinical trial in China, the company ...

The Lupus Research Alliance (LRA) and its clinical research affiliate, Lupus Therapeutics, have launched the largest, long-term prospective observational study in lupus with the goal of developing new ...

The Lupus Research Alliance (LRA) has announced $9 million in grants — three awards each totaling $3 million — to fund new research projects that aim to better understand lupus and pave the way toward ...

Ventus Therapeutics plans to develop a new treatment candidate for lupus and other inflammatory diseases marked by the activation of the type 1 interferon immune system pathway, the company recently ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Even though I know the characters with lupus are fictional, I’m filled with empathy and a little ...

When people think of systemic lupus erythematosus (SLE), they often only think about the “butterfly” rash, severe joint pain, pleurisy, or kidney problems. But for many of us living with lupus, the ...

A study in a mouse model of systemic lupus erythematosus (SLE) showed that treatment with methylprednisolone significantly improves survival rates in animals fed a regular diet — but not among those ...

When the protein TLR7, or toll-like receptor 7 — which normally triggers an immune response against viruses and bacteria — instead builds up in immune cells, the immune system may turn against its own ...

Lupus Therapeutics is partnering with AbbVie for the Phase 3 clinical program of upadacitinib for people with systemic lupus erythematosus (SLE). “The partnership with AbbVie will support the ...